Compare C & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | C | TMO |
|---|---|---|
| Founded | 1812 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Industrial Machinery/Components |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 225.2B | 242.8B |
| IPO Year | 2025 | 1996 |
| Metric | C | TMO |
|---|---|---|
| Price | $123.84 | $687.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 28 |
| Target Price | $150.71 | ★ $688.69 |
| AVG Volume (30 Days) | ★ 7.5M | 2.1M |
| Earning Date | 10-13-2026 | 10-21-2026 |
| Dividend Yield | ★ 2.17% | 0.27% |
| EPS Growth | ★ 17.68 | 7.32 |
| EPS | 6.99 | ★ 9.10 |
| Revenue | ★ $85,225,000,000.00 | $20,918,000,000.00 |
| Revenue This Year | $12.57 | $7.45 |
| Revenue Next Year | $4.34 | $5.16 |
| P/E Ratio | ★ $17.62 | $76.35 |
| Revenue Growth | 5.04 | ★ 14.47 |
| 52 Week Low | $95.00 | $435.27 |
| 52 Week High | $147.96 | $704.00 |
| Indicator | C | TMO |
|---|---|---|
| Relative Strength Index (RSI) | 37.59 | 62.49 |
| Support Level | $119.76 | $589.71 |
| Resistance Level | $125.16 | $694.33 |
| Average True Range (ATR) | 3.05 | 19.14 |
| MACD | -0.55 | 0.29 |
| Stochastic Oscillator | 28.52 | 75.25 |
Citigroup is a global financial powerhouse that orchestrates the movement of over $6 trillion in daily transaction volume, serving as the essential connective tissue for the world's most complex multinational corporations. The firm services 90% of the Fortune 500 through a proprietary network that includes direct membership to over 270 cash-clearing centers and a footprint that spans 94 countries. After a checkered history operating as an overly complex, disjointed firm, it has taken steps to streamline operations, resulting in organization across five segments: services, markets, banking, wealth, and US personal banking.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).